Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials
Primary result · Primary composite outcomeResult — go to the resultHazard ratio 0.50 95% CI 0.44–0.57Authors' conclusion
Combined disease-modifying treatment with an SGLT2 inhibitor and MRA in patients with type 2 diabetes and CKD may substantially increase the number of years free from kidney failure and mortality.
Study context
- Population
- Patients with T2D and chronic kidney disease (CKD); effect estimates from CREDENCE and FIDELIO, applied to DAPA-CKD control group with T2DCREDENCE 4,401 · FIDELIO 5,734
- Comparison
- SGLT2i + mineralocorticoid-receptor antagonists (MRA) combination vs ACE inhibitors/angiotensin receptor blockers
- Primary endpoint
- Composite of:
- Doubling of serum creatinine
- End-stage kidney disease
- Death because of kidney failure
Methodological detailstrial-level estimates from CREDENCE and FIDELIO applied to DAPA-CKD control group, repeated in an observational study
- Trial-level estimates from CREDENCE and FIDELIO applied to DAPA-CKD control group
- Repeated in an observational study
Primary result
Primary composite outcome
Hazard ratio
0.50
95% CI 0.44–0.57
Combination treatmentvs ACE inhibitors/ARBs
HR 0.50 (95% CI 0.44–0.57)
As reported in the abstract
Further findings
| Outcome | Combination treatment | Incremental gain (years) (95% CI) |
|---|---|---|
| Estimated event-free survival from primary outcome · at age 50 yearsCombination treatment vs ACE inhibitors/ARBs | 16.7 (CI 18.1–21.0) years | 6.7 (5.5–7.9) |
- Estimated event-free survival from primary outcome: ACE inhibitors/ARBs 10.0 (CI 6.8–12.3) years
Gain in event-free survival from primary outcome, observational study
- Estimated gain in event-free survival
- 6.3 years (95% CI: 5.2, 7.3)
Gain in event-free survival from primary outcome, conservative scenario
- Gain in event-free survival
- 2.5 years (95% CI: 2.0, 2.9)
- Low adherence (70% of the observed adherence) and less pronounced efficacy (70% of the observed efficacy with 2% yearly decline)
Original publication
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials. Diabetes Obes Metab. Published 14 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →